Pharmaceutical Stocks

Pharmaceutical stocks have grown tremendously as medicine advances. With diseases like Covid-19, diabetes, liver disease and other illnesses affecting more and more of the population, pharmaceutical companies are racing to find cures – further advancing medicine and driving pharma stock prices higher.

Big Pharma corporations like AstraZeneca, Merck & Co., Pfizer, and Johnson & Johnson are leading the charge against the novel coronavirus, competing with smaller biotech names — such as Moderna and Novavax. The race to find a Covid-19 vaccine has sent both pharma and biotech stocks to the moon.

Tiny Amarin Banking on Fish Oil Drug Success

By Barry Cohen, Health Care Writer
The stock's upside is potentially huge if this drug takes off.

Try a Covered Call On Watson Pharma’s Upside

By John Kmiecik, InvestorPlace Contributor
This strategy could generate extra profit from the stock's near-term upside

Big Pharma Eyes Rare-Disease Revenue Stream

By Barry Cohen, Health Care Writer
Large drug firms are starting to look beyond common maladies to keep the cash coming.

Johnson & Johnson a Safe Play for Income

By Barry Cohen, Health Care Writer
JNJ's financials are solid, and the company is making strides toward getting 11 new drugs approved by the end of 2015.

Vertex Scores Big With Hepatitis Drug

By Barry Cohen, Health Care Writer
The company's new hepatitis C medication, Incivek, is outselling Merck's drug by 4-to-1. What's more, it's close to adding another drug to its arsenal.

Teva Pharmaceutical: A Good Buy for Value Investors

By Lawrence Meyers, InvestorPlace Contributor
Teva Pharmaceuticals, a major force in the generic drug realm, delivers on the fundamentals and is a worthy value stock.

No Reason to Hold Merck

By Lawrence Meyers, InvestorPlace Contributor
As long as this big-name pharmaceutical's growth continues to stagnate, its stock price isn't going anywhere, either.

Big Pharma Cash Hoards Seem Earmarked for Opportunities in Emerging Markets

By Barry Cohen, Health Care Writer
Pfizer and Merck doing little to put money toward expanding their business, and even Johnson & Johnson held back some cash in a purchase of Synthes.

More Tightly Focused Biogen Appears to Have Greater Upside

By Barry Cohen, Health Care Writer
With many of its drugs in Phase III clinical trials, including a promising treatment for MS, Biogen has upside potential.

Big Pharma Banking on New Cancer Treatment Approach to Boost Sales

By Barry Cohen, Health Care Writer
GlaxoSmithKline, Eli Lilly and Novartis are among the companies studying epigenetics -- a new approach to fighting cancer that is already seeing some success.

Campaign to Kill Medco-Express Scripts Deal Likely Futile

By Barry Cohen, Health Care Writer
It's not very likely that major pharmaceuticals will be able to prevent Express Scripts from acquiring Medco. But they do have good reason to try.

Pfizer Still Is a Sick Corporate Patient

By Peter Cohan, InvestorPlace Writer
Pfizer's good second-quarter showing is overshadowed by upcoming losses of patent protection and no guaranteed shot at regenerating revenue.

Sides Form on Medco-Express Scripts Deal

By Barry Cohen, Health Care Writer
With the Federal Trade Commission likely to give the deal a close eye, analysts and investors sound off varying degrees of optimism and pessimism about this venture.

A Tuesday Thrashing for Dow Jones Stocks

By Jonathan Yates, InvestorPlace Contributor
Economic concerns drag Dow slightly lower, with Pfizer, Home Depot, GE and Bank of America all losing early Tuesday.

Allergan’s Good Looks May Be Too Pricey

By Barry Cohen, Health Care Writer
Expected uptick in breast implants, wrinkle fillers is good news for Botox creator, but many investors think AGN still costs too much.

Medical Research Firms May See a Profit Pinch

By Barry Cohen, Health Care Writer
Relationships with Big Pharma are changing the game.

Is Pfizer Move to Sell Non-Pharma Divisions Bad Medicine?

By Barry Cohen, Health Care Writer
Pfizer has said it will shed its nutritional and animal health businesses to pump more money into its drug pipeline. But is the move risky?

Lilly Study Could Sink Prospects for Alzheimer’s Treatments

By Barry Cohen, Health Care Writer
Eli Lilly's drug study failure raises questions about the safety of its Alzheimer's treatment, but will rival Bristol-Myers have success?

Is Big Pharma Resistant to Antibiotics?

By Barry Cohen, Health Care Writer
Less profitable drugs take a backseat despite health risks
Load More